Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.39 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.39 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.39 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.39 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1794814 | 0.77 | ACHE (0.50) | ALDH1A1CYP3A4CA1CA2CA7 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28493 | 0.76 | ALDH1A1 (1.00) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| Bromide SCHEMBL1021629 | 0.75 | ACHE (0.48) | ALDH1A1CYP3A4CA1CA2CA7 | |
| SCHEMBL14763753 | 0.74 | ALDH1A1 (0.58) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| Magnesium Chloride Anhydrous SCHEMBL27723160 | 0.74 | ALDH1A1 (0.58) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| SCHEMBL2037 | 0.74 | CA1 (0.58) | ALDH1A1CYP3A4CYP2A6CYP2C19CA1 | |
| SCHEMBL3000499 | 0.74 | ALDH1A1 (0.58) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28557531 | 0.73 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28416912 | 0.73 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28740008 | 0.73 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11945836-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3719029-A1 | COMPOSITIONS FOR INDUCING SEDATION | Sage Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3224269-B1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-8237003-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120035053-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-02-09 | — | — | US | disclosed |
| CN-102186834-A | New herbicides | SYNGENTA LTD | 2011-09-14 | — | — | CN | disclosed |
| WO-2011100022-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2350034-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20110152310-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010046194-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009139916-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945836-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | ALDH1A1 578/4885CYP1A1 311/4885CYP1B1 208/4885 |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ALDH1A1 578/4885CYP1A1 311/4885CYP1B1 208/4885 |
| US-20120035053-A1 | NOVEL HERBICIDES | DDT, HCAR3, HPD | ALDH1A1 352/4885CYP1A1 426/4885CYP1B1 338/4885 |
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | ALDH1A1 2555/4885CYP1A1 2939/4885CYP1B1 2352/4885 |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ALDH1A1 578/4885CYP1A1 311/4885CYP1B1 208/4885 |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | ALDH1A1 578/4885CYP1A1 311/4885CYP1B1 208/4885 |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ALDH1A1 578/4885CYP1A1 311/4885CYP1B1 208/4885 |
| US-20110152310-A1 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, CDC37, HSP90B1 | ALDH1A1 2205/4885CYP1A1 1528/4885CYP1B1 1130/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | ALDH1A1 1896/4885CYP1A1 759/4885CYP1B1 822/4885 |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | MGLL, FASN, MSMO1 | ALDH1A1 1338/4885CYP1A1 85/4885CYP1B1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.